Roivant Sciences is a biopharmaceutical company that develops transformative medicines and technologies by building agile, focused companies called Vants. Since 2019, Roivant's Vants have conducted 10 positive Phase 3 trials and achieved six FDA approvals, including the launch of VTAMA® (tapinarof) cream for plaque psoriasis. By integrating technology across discovery, development, and commercialization, Roivant aims to address inefficiencies in healthcare and deliver innovative treatments to patients.